IMPACT Therapeutics Cash Flow Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Net Income	-295.92	-254.76
Depreciation & Amortization	3.97	6.13
Other Amortization	0.51	0.53
Loss (Gain) From Sale of Assets	-0.2	-
Loss (Gain) From Sale of Investments	-	-0.07
Stock-Based Compensation	62.81	8.35
Other Operating Activities	70.18	55.55
Change in Accounts Receivable	-7.44	-
Change in Inventory	-22.63	-4.35
Change in Accounts Payable	-17.95	8.8
Change in Other Net Operating Assets	110.81	98.51
Operating Cash Flow	-95.88	-81.31
Capital Expenditures	-1.51	-1.7
Sale of Property, Plant & Equipment	0.2	0.01
Investment in Securities	114.13	-108.17
Investing Cash Flow	112.82	-109.85
Long-Term Debt Repaid	-1.5	-6.64
Net Debt Issued (Repaid)	-1.5	-6.64
Issuance of Common Stock	19.46	454.3
Other Financing Activities	-4.49	-299.32
Financing Cash Flow	13.47	148.33
Foreign Exchange Rate Adjustments	-1.99	1.64
Net Cash Flow	28.41	-41.2
Free Cash Flow	-97.39	-83.01
Free Cash Flow Margin	-254.61%	-247.43%
Free Cash Flow Per Share	-0.43	-0.41
Cash Income Tax Paid	0	0
Levered Free Cash Flow	-136.56	-
Unlevered Free Cash Flow	-93.64	-
Change in Working Capital	62.78	102.96